264 related articles for article (PubMed ID: 21176237)
1. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
[TBL] [Abstract][Full Text] [Related]
2. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
Cronin M; Sangli C; Liu ML; Pho M; Dutta D; Nguyen A; Jeong J; Wu J; Langone KC; Watson D
Clin Chem; 2007 Jun; 53(6):1084-91. PubMed ID: 17463177
[TBL] [Abstract][Full Text] [Related]
3. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.
Knezevic D; Goddard AD; Natraj N; Cherbavaz DB; Clark-Langone KM; Snable J; Watson D; Falzarano SM; Magi-Galluzzi C; Klein EA; Quale C
BMC Genomics; 2013 Oct; 14():690. PubMed ID: 24103217
[TBL] [Abstract][Full Text] [Related]
4. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
Schildgen V; Warm M; Brockmann M; Schildgen O
Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
[TBL] [Abstract][Full Text] [Related]
5. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
Acs G; Esposito NN; Kiluk J; Loftus L; Laronga C
Mod Pathol; 2012 Apr; 25(4):556-66. PubMed ID: 22173289
[TBL] [Abstract][Full Text] [Related]
6. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
Hou Y; Tozbikian G; Zynger DL; Li Z
Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
[TBL] [Abstract][Full Text] [Related]
7. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
8. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
9. Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.
You YN; Rustin RB; Sullivan JD
Surg Oncol; 2015 Jun; 24(2):61-6. PubMed ID: 25770397
[TBL] [Abstract][Full Text] [Related]
10. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
11. Analytical performance of a formalin-fixed paraffin-embedded tissue-based 634-probe prognostic assay for predicting outcome of patients with stage II colon cancer.
Plamadeala V; Huang S; McCreary SM; Reitze NJ; Ewing AL; Gabrin MJ; Bennett AE; Mulligan JM; Wilson CL; Wang D
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):308-16. PubMed ID: 24717231
[TBL] [Abstract][Full Text] [Related]
12. Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
Bernhardt SM; Dasari P; Wrin J; Raymond W; Edwards S; Walsh D; Townsend AR; Price TJ; Ingman WV
Breast Cancer Res; 2020 Aug; 22(1):90. PubMed ID: 32811558
[TBL] [Abstract][Full Text] [Related]
13. Oncotype DX testing does not affect clinical practice in stage IIa colon cancer.
Allar BG; Messaris E; Poylin VY; Schlechter BL; Cataldo TE
Med Oncol; 2022 Feb; 39(5):59. PubMed ID: 35150339
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
[TBL] [Abstract][Full Text] [Related]
15. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
16. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
[TBL] [Abstract][Full Text] [Related]
17. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
18. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
[TBL] [Abstract][Full Text] [Related]
19. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
20. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
